Generate Biomedicines, Inc. (GENB) Stock Score, Valuation & Financial Research

Generate Biomedicines, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for GENB

Generate Biomedicines, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 13.80. These figures are a research snapshot, not a buy or sell recommendation.

What Generate Biomedicines, Inc. does

Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-annual dosing in severe asthma; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy. Integral to their work is the Generate Platform, a sophisticated system engineered to be versatile across diverse therapeutic areas and protein modalities. This platform combines computational innovation with scalable biohardware, allowing them to tackle therapeutic hurdles beyond the capabilities of traditional technologies. Established in 2018, the company was initially known as Generate Biologics, Inc. before rebranding to Generate Biomedicines, Inc. in February 2020. Its headquarters are located in Somerville, Massachusetts.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Generate Biomedicines is a clinical-stage biotechnology company that utilizes a proprietary generative biology platform to discover and develop novel protein therapeutics. The company operates as a research and development entity, currently focusing on advancing its pipeline of clinical candidates and platform capabilities, and has not yet generated significant commercial product revenue.

Products and services

The company develops a pipeline of protein-based therapeutic candidates, including GB-0895 for asthma and COPD, and GB-5267 for cancer, using its machine learning-driven generative biology platform.

Customer types

Clinical trial patients.

Suppliers, materials and equipment

Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of clinical trial materials; specific supplier names are unnamed. Source

Business relationships and partnerships

Roswell Park Comprehensive Cancer Center — A research collaboration focused on the development of GB-5267, a MUC16 armored CAR T therapy. Source

Business strengths to evaluate

Proprietary generative biology platform integrating machine learning and biological engineering Source

Business risks and research considerations

History of operating losses and dependence on external financing Source

Sources: Company research source · Roswell Park Comprehensive Cancer Center · Contract Manufacturing Organizations · Proprietary generative biology platform integrating machine learning and biological engineering

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

GENB financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:: Not currently available
Stored price:: USD 13.80
Market capitalization:: 1.77B (currency not supplied)
Revenue:: USD 31.89M
Net income:: USD -203.15M
Free cash flow:: USD -204.13M
Cash:: USD 135.36M
Total debt:: USD 62.63M
EPS:: USD -4.98

What stands out

Reported year-over-year revenue growth is +55.9%.
Free cash flow is USD -204.13M, negative for the stored period.
The balance sheet shows USD 135.36M of cash versus USD 62.63M of total debt, an excess of cash over debt on these two reported measures.
The current research record carries a share basis reconciled warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

Free cash flow is -640.1% of stored revenue. This is a simple cross-field ratio, not a verified same-period cash conversion margin; confirm reporting periods before comparison.
Net income equals -637.0% of stored revenue. This is an indicative ratio only; accounting periods and units should be verified in filings.
Cash exceeds debt by USD 72.73M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for GENB

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

Can GENB sustain its current revenue growth while also converting that growth into durable profit and free cash flow?
How long can GENB fund negative free cash flow using its current cash position before it may need more debt or new shares?
How is GENB likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
What specifically needs to improve for GENB to reach sustainable profitability?
What does the current share basis reconciled warning mean for the reliability or interpretation of GENB's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research GENB

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.